Navigation Links
Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
Date:10/1/2009

t cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA®, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements. These include statements concerning the potential for TELCYTA to treat NSCLC, and the effectiveness of TELCYTA in combination with carboplatin and paclitaxel and as maintenance therapy in NSCLC patients. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including the risks associated with clinical trials and the interpretation of resulting data. Detailed information regarding these and other factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended June 30, 2009. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

SOURCE Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
6. Telik Announces Presentation at ASCO Annual Meeting
7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)...  Kindred Hospital Houston Northwest, with Wound Care ... its new outpatient wound healing center.  The wound ... chronic, hard to heal wounds. Chronic wounds include ... lower leg wounds related to blood flow issues, ... injury wounds which are complex and demonstrate delayed ...
(Date:7/11/2014)... LONDON , July 11, 2014 ... ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average ... 500 closed at 1,964.68, down 0.41%. The losses were broad ... in negative. The S&P 500 Health Care Sector Index ended ... advanced 2.75% in the last one month. Investor-Edge has initiated ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the addition of the "Immunoprotein Diagnostic Testing ... at the highest CAGR of 6% and is ... report to their offering. ... for immunoprotein diagnostic testing has been segmented according ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... 2011 Assured Pharmacy (Pink Sheets: APHY ), ... than 3,000 sufferers of chronic pain announced that total sales ... 2010 were $1,514,984 which equates to $70,464 per business day. ... total sales of $1,348,344 for December 2009 which equates to ...
... 2011 BioDelivery Sciences International, Inc. ... outcome of a pre-Investigational New Drug (pre-IND) meeting ... on the development program for BEMA Buprenorphine/Naloxone, BDSI,s ... discussed is based on pharmacokinetic and safety data ...
Cached Medicine Technology:Assured Pharmacy Reports Same Store Sales for the Month of December 2010 2Assured Pharmacy Reports Same Store Sales for the Month of December 2010 3BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting 2BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting 3
(Date:7/14/2014)... The Cabin Chiang Mai, Asia’s leading inpatient ... Community website – a free comprehensive aftercare service ... lifelong recovery wherever they live in the world. , ... to help them maintain their recovery after successfully completing ... reputable treatment programme. As a chronic disease, addicts in ...
(Date:7/14/2014)... 2014 EurekaMag.com has newly published results ... a contagious liver disease that ranges in severity ... a serious, lifelong illness that attacks the liver. An ... chronic Hepatitis C virus infection of which approximately 80% ... research category covers all studies on Hepatitis C , ...
(Date:7/14/2014)... According to the Boost Your Bust book review recently ... want to learn how to increase the size of their breasts ... chapters including:, , Chapter 1 – What Are ... 2 – How Natural Breast Enlargement Works , Chapter ... Chapter 4 – The Groundwork , Chapter ...
(Date:7/14/2014)... Vaginal Mesh lawsuit claims continue ... pelvic mesh manufacturers in the U.S. District Court, Southern ... The federal complaints are pending against pelvic mesh manufacturers ... Systems (MDL No. 2325), and C.R. Bard, Inc., (MDL ... Vaginal Mesh lawsuit claims pending, according to statistics from ...
(Date:7/14/2014)... activities that promote mental activity, and moderate physical ... the development of Alzheimer,s disease and dementia in ... at the Alzheimer,s Association International Conference 2014 (AAIC ... AAIC 2014 also showed that sleep problems ... may increase dementia risk in veterans. Additionally, ...
Breaking Medicine News(10 mins):Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 3Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 4Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 6
... with craniosynostosis, a condition that causes the plates in the ... infant,s bone with the biodegradable matrix could eliminate some of ... remarkable thing about this is the finding that the composition ... Cells begin producing natural drugs to drive bone healing in ...
... stroke more likely for organ recipients with sleep apnea, ... -- Kidney transplant patients with sleep apnea are at ... stroke, Hungarian researchers say. , The study of 100 ... to severe sleep apnea, a rate similar to that ...
... Procedure cuts diagnosis time and costs, study finds , ... emergency room triage, CT angiography is quicker, more accurate ... pain who have low to moderate enzyme and EKG ... included 749 acute chest pain patients at 16 emergency ...
... MINNEAPOLIS, Nov. 19 2009 has been a monumental ... with "moneyvation," from QUITPLAN Services, QuitCash Challenge, helped the ... and win The Challenge. Nearly 2,000 Minnesotans, including Doug, ... chance to win the $5,000 grand prize. , On ...
... Official Statement by Teamsters General President Jim Hoffa ... issued the following statement today about the Senate plan to ... that will mean a huge middle-class tax hike to workers: ... an excise tax on insurers for higher-cost health plans that ...
... Monogram Energy, Inc. ("Monogram") (Pink Sheets: MGRN) announced today ... Inc. ("Triad"), which was effective as of October 30, ... and Recapitalization Agreement, shareholders of Monogram acquired 100% of ... 95% ownership to the Triad shareholders in the combined ...
Cached Medicine News:Health News:Bone implant offers hope for skull deformities 2Health News:Kidney Transplant, Sleep Disorder May Add Up to Trouble 2Health News:First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM) 2Health News:First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM) 3Health News:Monogram Energy, Inc. Acquires Triad Therapeutics, Inc. 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: